Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026936 (Mycoplasma)
 14,761 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Thirty-two patients were treated by ofloxacin on bacteriological documented infections. They were Enterobacterias: n = 15 (MIC less than or equal to 0.06 to 0.5 microgram/ml); Pseudomonas aeruginosa and Acinetobacter: n = 1 (MIC 0.5 and 4 micrograms/ml); Staphylococcus: n = 6 (MIC less than or equal to 0.06 to 4 micrograms/ml); Pneumococcus: n = 1; Mycoplasma: n = 1; Chlamydia psittaci: n = 2; Legionella pneumophila: n = 1; Rickettsias: n = 4 (three mediterranean fevers one query fever). Ofloxacin was given orally from 400 to 800 mg per day (5 to 15 mg/kg/day). It was used alone 26 times and on 6 occasions it was associated with rifampin on 6 staphylococcal infections. On 19 cases it was used after failure or intolerance of initial therapy. Thirty times it was the first antibiotic substance used. Results were good mainly: 1) on nine pneumonitis (enterobacterias: 4; Pneumococcus: 1; Mycoplasma: 1; Chlamydia: 2; Legionella: 1) during a mean duration of twenty days; 2) urinary infections (n:7) provoked by E. coli and Enterobacter cloacae (mean duration: 20 days); 3) 4 osteo-articular-infections (mean duration: 77 days); 4) Rickettsial infections (n:4) during a mean duration of 11 days. Results are particularly noteworthy because patients treated had severe infections: 12 bacteremias, 1 endocarditis and 1 purulent meningitis. None severe adverse effect was observed.
 ...
PMID:[Ofloxacin (RU 43280). Clinical study]. 330 73

The activity of roxithromycin against Legionella pneumophila in vitro was approximately the same as that of rokitamycin and superior to those of erythromycin and josamycin. In experimental pneumonia due to L. pneumophila none of the animals in the roxithromycin and rifampicin groups died by day 10 of the infection. The MIC ranges of roxithromycin, erythromycin and rokitamycin for Mycoplasma pneumoniae were 0.008-0.063, 0.004-0.008 and 0.016-greater than 125, respectively. In experimental pneumonia caused by M. pneumoniae, roxithromycin showed good activity similar to that of erythromycin.
 ...
PMID:Activity of macrolides against organisms responsible for respiratory infection with emphasis on Mycoplasma and Legionella. 342 89

The folate inhibitor trimethoprim (TMP) is active against and potentially cidal to a few higher microorganisms and a wide spectrum of pathogenic bacteria except for Bacteroides, Branhamella, Brucella, Chlamydia, Clostridium, Mycobacterium, Mycoplasma, Nocardia, Neisseria, Pseudomonas and Treponema. These organisms tend to be more sensitive to sulfonamides (SUL) than to TMP, whereas TMP is 10- to 100-fold more active than SUL against most other bacteria. Synergy between TMP and SUL occurs at drug concentrations equal to or less than their respective MICs and is often seen in vitro with isolates that are sensitive or moderately resistant to one or both of the components. Synergy occurs over a wide range of ratios between TMP and SUL, the optimal being that between their respective MICs when acting singly. In vitro synergy is more impaired by bacterial resistance than by suboptimal TMP:SUL ratios. The vast majority of clinical isolates of Haemophilus, staphylococci, streptococci and enteric bacteria are inhibited in vitro by the minimum concentrations of drug attained in plasma during therapy. Exceptions are found among Enterobacter, Citrobacter, Serratia, Proteus and in particular Klebsiella where SUL resistance is common and isolates with TMP MICs of 5 mg/l or more may occur and lead to failure of TMP-SUL therapy in systemic infections. In the urinary tract drug concentrations that are synergistic and therefore inhibitory in vitro against isolates moderately resistant to SUL (MIC less than or equal to 1 g/l) and/or TMP (MIC less than or equal to 0.1 g/l) are present during TMP-SUL therapy. However, whether the synergy and the bactericidal effect of TMP-SUL observed in vitro play a role in vivo is controversial.
 ...
PMID:The antimicrobial activities of trimethoprim and sulfonamides. 351 8

The product nitroxoline was studied in vitro for its activity towards Ureaplasma urealyticum and Mycoplasma hominis. In view of the low MIC values obtained, it seems nitroxoline could be used in the treatment of urinary infections. It is bactericidal, and should not produce resistant strains.
 ...
PMID:[In vitro activity of nitroxoline on urogenital mycoplasmas]. 354 11

A new macrolide antibiotic, EL-870, 20-deoxo-20-(3,5-dimethylpiperidin-1-yl)desmycosin, has been prepared by chemical modification of desmycosin. In vitro, against selected animal bacterial pathogens, it inhibited growth of Pasteurella multocida, Pasteurella haemolytica, Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, Streptococcus suis, Actinomyces pyogenes and certain other bacteria at levels of 6.25 micrograms/ml or less. In general, the MICs for Gram-negative enteric bacteria have been greater than 50 micrograms/ml. Concentrations equivalent to 4 X the MIC value were bactericidal for Pasteurella sp. EL-870 had other antibacterial properties which were characteristic of macrolide antibiotics.
 ...
PMID:In vitro antibacterial properties of EL-870, a new semi-synthetic macrolide antibiotic. 357 Sep 67

Susceptibility of Mycoplasma pneumoniae (10 strains), Mycoplasma hominis (20 strains) and Ureaplasma urealyticum (100 strains) to minocycline and doxycycline was studied in vitro. Minimal inhibitory concentrations were determined using an agar dilution method for M. pneumoniae and M. hominis and a metabolic inhibition test for U. urealyticum. M. pneumoniae strains were highly susceptible to minocycline and doxycycline (MIC less than or equal to 0.1 mg/l). Among M. hominis strains, 17 were susceptible (MIC less than or equal to 0.1 mg/l), whereas 3 were inhibited only by concentrations ranging from 4 to 16 mg/l. Among the 100 U. urealyticum strains, 95 were inhibited by 4 mg/l minocycline and 94 by 4 mg/l doxycycline. Both antibiotics exhibited similar activities against the three species (same ranges, same mode MICs).
 ...
PMID:[Comparative activity of minocycline and doxycycline on mycoplasmas pathogenic for man]. 393 30

Clinical usage of aztreonam (AZT), a newly synthesized antibiotic which belongs to monobactam, was evaluated for its efficacy and safety in 22 patients aged from 1 month-old to 13 year-5 month-old with bacterial infections and the following results were obtained. AZT was administered to 4 patients with pyelonephritis and 10 patients with tonsillitis at a daily dosage of 40.4-120.9 mg/kg and to 5 patients with clinical sepsis associated with agranulocytosis caused by intensive antileukemic therapy at a daily dosage of 142.4-171.4 mg/kg, divided into 3 or 4, by intravenous injection or by 30 minutes drip infusion. The clinical results of these 19 evaluable patients were as follows: excellent; 10 cases, good; 5 cases, fair; 2 cases, poor; 2 cases. The over all efficacy rate was 78.9% and that of pyelonephritis and tonsillitis was 100.0%. No clinical side effects were observed in any 23 patients, including a patient who proved to be suffering from Mycoplasma pneumoniae infection, and no abnormal laboratory findings caused by AZT was noticed. The MICs of AZT against 9 strains isolated from patients with pyelonephritis and those with tonsillitis were as follows: MICs against all of 3 strains of K. pneumoniae were less than 0.05 microgram/ml. MICs against 2 out of 4 strains of H. influenzae were less than 0.05 microgram/ml and those of the remaining 2 strains were 0.10 microgram/ml. MIC against 1 strain of S. aureus was 1.56 microgram/ml. MIC against 1 strain of S. epidermidis was more than 100 micrograms/ml.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Clinical evaluation of aztreonam in children]. 409 60

Ciprofloxacin was found to be the most active of a group of 4-quinolone antibiotics tested against the SA2f strain of Chlamydia trachomatis (MBC and MIC 1.0 mg/l). Against genital isolates of Chlamydia trachomatis, ciprofloxacin was twice as active as rosoxacin. Ciprofloxacin showed similar activity to that of oxytetracycline against clinical isolates of Mycoplasma hominis and Ureaplasma urealyticum, and was 8-fold more active than rosoxacin against the latter.
 ...
PMID:The activity of ciprofloxacin and other 4-quinolones against Chlamydia trachomatis and Mycoplasmas in vitro. 623 3

A semiautomated approach for the characterization of subgingival bacterial isolates which economizes in media preparation, inoculation, reading, recording, and interpretation of results was tested. Test ingredients were added to a basal medium consisting of Mycoplasma broth supplemented with 5 micrograms of hemin, 0.5 mg of NaHCO3, and 0.5 mg of L-cysteine per ml. Sterile test media were aseptically dispensed into wells of sterile microtiter plates with a MIC 2000 dispenser. Inocula were grown in broth or scraped from agar plates, dispersed, and inoculated with a MIC 2000 inoculator. After 2 to 4 days of incubation, the optical density of growth was determined with an Artek 210 vertical beam reader at 580 nm and stored on a floppy disk. Reagents were added to each well, and the changes in optical density were determined. Thresholds for positive reactions were determined after extensive preliminary studies for each test. The tests were run in duplicate on each plate and interpreted with an Artek vertical beam reader. Tests that were run in this system included: fermentation of carbohydrates, decarboxylase reactions, reduction of nitrate and nitrite, ammonia production, hydrolysis of esculin, growth in the presence of inhibitory or stimulatory substances, and indole production. Approximately 80% of all isolates from subgingival samples could be characterized by this technique. Comparisons were made between the semiautomated and conventional identification techniques. Overall reproducibility of 2,980 strains by the semiautomated and conventional techniques were 95 and 90%, respectively. There was an 86% similarity of results by the semiautomated and conventional methods. The semiautomated technique was more rapid, less expensive, and as reproducible as the conventional method of identification.
 ...
PMID:Semiautomated technique for identification of subgingival isolates. 637 36

Thirty-one strains of Mycoplasma pneumoniae were tested for drug sensitivity to both josamycin (JM) and erythromycin (EM), to evaluate the efficacy of JM for mycoplasmal pneumonia in children. In addition to the sensitivity tests of 31 M. pneumoniae strains against JM and EM, 50 patients, between the ages of 3 years 1 month and 13 years 3 months, suspected of suffering from mycoplasmal pneumonia were treated with 50 or 200 mg JM tablets at an average daily dose of 43.1 mg/kg t.i.d. or b.i.d. for an average period of 14 days; an additional 31 patients between the ages of 2 years 9 months and 11 years, suspected of suffering from this disease were treated with tablet or dry syrup of EM, with the exception of EM estolate, t.i.d. or b.i.d. at an average daily dose of 72.5 mg/kg for an average period of 15 days. Patients were selected in 37 and 22 mycoplasmal pneumonic patients respectively for JM and EM. Clinical and bacteriological effects, efficacy and side effects of the drugs on this disease were studied and the following results were obtained. Drug sensitivity test Of all 31 strains tested for JM sensitivity the populations which exhibited 0.125 mcg/ml were most abundant (18/31, 58.1%) and MIC pattern of all strains were distributed from 0.0313 to 0.125 mcg/ml. In the EM group, 61.3% (19/31) of the populations were sensitive at 0.015 mcg/ml, exhibiting the dominant distribution pattern and MIC range of all organism varied from 0.0078 to 0.0313 mcg/ml. Resistant strains were found to neither JM nor EM. EM was approximately 2 to 10 times more active than JM in MIC evaluation. Clinical effects of JM by daily doses Clinical effects relative to the daily dose were evaluated in 3, 7, 10 days after administration of drugs. The response was favorable, according to assessments of the attending doctors, in 96.7, 100% and 95.8% of the patient group given JM in a daily dose of 40-49 mg/kg, the group to which the largest number of patients belonged. Similar favorable results were obtained by the assessments of Evaluation Committee, showing 86.7, 96.7% and 100% of favorable response. Upon comparison, in the same interval, of these results with those of the groups given EM in a daily dose of 50 mg/kg, the group in which the largest number of patients were seen, there was no significant difference in the assessments either of the attending doctors or of the Evaluation Committee.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:[Clinical evaluation of josamycin for the treatment of Mycoplasma pneumonia in children]. 641 31


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>